- Ideas
- Markets
- Cryptocurrencies
- Currencies
- Stocks
- Earnings Calendar
- Stock Screener
- Large-Cap
- Top Gainers
- Top Losers
- Most Active
- Most Volatile
- Overbought
- Oversold
- All Time High
- All Time Low
- Sector & Industry
Apple, Advanced Micro Devices Inc, Amazon Com Inc, TESLA INC, NETFLIX INC, Facebook Inc
- Indices
S&P 500, Nasdaq Composite, Dow 30, Nikkei 225, DAX Index, FTSE 100
- Futures
- Bonds
US 10Y, Euro Bund, Germany 10Y, Japan 10Y Yield, UK 10Y, India 10Y
- CFDs
Gold, Brent Oil, Crude Oil, CFDs on Natural Gas, Palladium, Silver
- Scripts
- Oscillators
- Centered Oscillators
- Volatility
- Trend Analysis
- Volume
- Moving Average
- Exponential Moving Average (EMA)
- Weighted Moving Average (WMA)
- Simple Moving Average (SMA)
- Hull Moving Average (HMA)
- Kaufman's Adaptive Moving Average (KAMA)
- Smoothed Moving Average (SMMA)
- Variable Index Dynamic Average (VIDYA)
- Volume-weighted Moving Average (VWMA)
- Fractal Adaptive Moving Average (FRAMA)
- Double Exponential Moving Average (DEMA)
- Breadth Indicators
- Bill Williams Indicators
- Screener
- Shows
- Chart
- More
RUBIUS THERAPEUTICS INC
NASDAQ
RUBY
RUBY
RUBIUS THERAPEUTICS INC
Next Earning
Market Cap
EPS
Div Yield
P/E
Next Earning
Market Cap
EPS
Div Yield
P/E
RUBY, 1D
Long
NASDAQ:RUBY Setting a nice bullish consolidation. Any break of resistance is a trigger long for me. Earnings out so soon throws a spanner in the works though so would ideally like to wait and see how it reacts to it's earnings Short float= 12.7% Keep risk tight (area marked on chart) Be aware this is a pharma stock so they have been known to be wild (news...
0
Valuation
Enterprise Value/EBITDA, TTM
—
Enterprise Value, FQ
—
Market Cap — Basic
—
Number of Employees
—
Number of Shareholders
—
Price/Earnings, TTM
—
Price/Revenue, TTM
—
Price/Book Ratio, FY
—
Price/Sales Ratio, FY
—
Balance Sheet
Current Ratio, FQ
—
Debt to Equity, FQ
—
Net Debt, FQ
—
Quick Ratio, FQ
—
Total Assets, FQ
—
Total Debt, FQ
—
Operating Metrics
Return on Assets, TTM
—
Return on Equity, TTM
—
Return on Invested Capital, TTM
—
Revenue per Employee, TTM
—
Price History
Average Volume (10 day)
—
Beta - 1 Year
—
Price - 52 Week High
—
Price - 52 Week Low
—
Dividends
Dividends Paid, FY
—
Dividends per Share, FY
—
Expected Annual Dividends
—
Dividends Yield
—
Margins
Net Margin, TTM
—
Gross Margin, TTM
—
Operating Margin, TTM
—
Pretax Margin, TTM
—
Income Statement
Basic EPS, Net Income
—
Earnings per Share, Basic, TTM
—
EBITDA, TTM
—
Gross Profit, FY
—
Last Annual EPS
—
Last Annual Revenue, FY
—
Net Income, FY
—
Total Revenue, FY
—
Free Cash Flow, TTM
—
Sector: Healthcare
Industry: Biotechnology & Medical Research
Employees: 206
Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer, and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer, enzyme replacement therapies, and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes, which include broad therapeutic applications, predictable bio-distribution and advantageous tolerability. It is initially focused on advancing RCT product candidates for patients suffering from rare diseases, cancer and autoimmune diseases based on three modalities - cellular shielding, potent cell-cell interaction and tolerance induction. Its product candidates in rare diseases include RTX-134 for the treatment of phenylketonuria (PKU), RTX-134 followed by RTX-Uricase and RTX-CBS for the treatment of chronic refractory gout symptomatic homocystinuria.
News
Community & Tools
For Business
© 2019 TradingView
Stock Charts & Forex Charts
Stock Charts & Forex Charts
Made with
From the creators of MultiCharts
Select market data provided by ICE Data Services